|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crown J, O'Leary M and Ooi WS: Docetaxel
and paclitaxel in the treatment of breast cancer: A review of
clinical experience. Oncologist. 9(Suppl 2): S24–S32. 2004.
View Article : Google Scholar
|
|
3
|
Gradishar WJ: Taxanes for the treatment of
metastatic breast cancer. Breast Cancer (Auckl). 6:159–171.
2012.PubMed/NCBI
|
|
4
|
Galletti E, Magnani M, Renzulli ML and
Botta M: Paclitaxel and docetaxel resistance: Molecular mechanisms
and development of new generation taxanes. ChemMedChem. 2:920–942.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer. Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zasadil LM, Andersen KA, Yeum D, Rocque
GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME and Weaver BA:
Cytotoxicity of paclitaxel in breast cancer is due to chromosome
missegregation on multipolar spindles. Sci Transl Med.
6:229ra432014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim HM, Lim J, Park SK, Kang JS, Lee K,
Lee CW, Lee KH, Yun MJ, Yang KH, Han G, et al: Antitumor activity
of cytokine-induced killer cells against human lung cancer. Int
Immunopharmacol. 7:1802–1807. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang MR, Park SK, Lee CW, Cho IJ, Jo YN,
Yang JW, Kim JA, Yun J, Lee KH, Kwon HJ, et al: Widdrol induces
apoptosis via activation of AMP-activated protein kinase in colon
cancer cells. Oncol Rep. 27:1407–1412. 2012.PubMed/NCBI
|
|
10
|
Krishan A: Rapid flow cytofluorometric
analysis of mammalian cell cycle by propidium iodide staining. J
Cell Biol. 66:188–193. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang MR, Kang JS, Yang JW, Kim BG, Kim JA,
Jo YN, Lee K, Lee CW, Lee KH, Yun J, et al: Gene expression
profiling of KBH-A42, a novel histone deacetylase inhibitor, in
human leukemia and bladder cancer cell lines. Oncol Lett.
3:113–118. 2012.PubMed/NCBI
|
|
12
|
Li L, Zhao F, Lu J, Li T, Yang H, Wu C and
Liu Y: Notch-1 signaling promotes the malignant features of human
breast cancer through NF-kB activation. PLoS One. 9:e959122014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meacham CE and Morrison SJ: Tumour
heterogeneity and cancer cell plasticity. Nature. 501:328–337.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burrell RA, McGranahan N, Bartek J and
Swanton C: The causes and consequences of genetic heterogeneity in
cancer evolution. Nature. 501:338–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Croce MV, Colussi AG, Price MR and
Segal-Eiras A: Identification and characterization of different
subpopulations in a human lung adenocarcinoma cell line (A549).
Pathol Oncol Res. 5:197–204. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stockholm D, Benchaouir R, Picot J, Rameau
P, Neildez TM, Landini G, Laplace-Builhé C and Paldi A: The origin
of phenotypic heterogeneity in a clonal cell population in vitro.
PLoS One. 2:e3942007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marupudi NI, Han JE, Li KW, Renard VM,
Tyler BM and Brem H: Paclitaxel: A review of adverse toxicities and
novel delivery strategies. Expert Opin Drug Saf. 6:609–621. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer: Rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang S and Yu D: Targeting Src family
kinases in anti-cancer therapies: Turning promise into triumph.
Trends Pharmacol Sci. 33:122–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li D, Masiero M, Banham AH and Harris AL:
The notch ligand JAGGED1 as a target for anti-tumor therapy. Front
Oncol. 4:2542014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu Z and Xu S: ERK1/2 MAP kinases in cell
survival and apoptosis. IUBMB Life. 58:621–631. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu N, Lao Y, Zhang Y and Gillespie DA:
Akt: A double-edged sword in cell proliferation and genome
stability. J Oncol. 2012:9517242012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G:
Cancer stem cells in solid tumors: An overview and new approaches
for their isolation and characterization. FASEB J. 27:13–24. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ling GQ, Chen DB, Wang BQ and Zhang LS:
Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in
human breast cancer cell lines. Oncol Lett. 4:1264–1268.
2012.PubMed/NCBI
|
|
25
|
Klonisch T, Wiechec E, Hombach-Klonisch S,
Ande SR, Wesselborg S, Schulze-Osthoff K and Los M: Cancer stem
cell markers in common cancers-therapeutic implications. Trends Mol
Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borst P: Cancer drug pan-resistance:
Pumps, cancer stem cells, quiescence, epithelial to mesenchymal
transition, blocked cell death pathways, persisters or what? Open
Biol. 2:1200662012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Röyttä M, Laine KM and Härkönen P:
Morphological studies on the effect of taxol on cultured human
prostatic cancer cells. Prostate. 11:95–106. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Talpaz M, Shah NP, Kantarjian H, Donato N,
Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E,
et al: Dasatinib in imatinib-resistant Philadelphia
chromosome-positive leukemias. N Engl J Med. 354:2531–2541. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Steinberg M: Dasatinib: A tyrosine kinase
inhibitor for the treatment of chronic myelogenous leukemia and
philadelphia chromosome-positive acute lymphoblastic leukemia. Clin
Ther. 29:2289–2308. 2007. View Article : Google Scholar : PubMed/NCBI
|
